CVS CVS Health

Q2 2025 10-Q

Filed: Jul 31, 2025Period ending Jun 30, 2025

Consumer Discretionary

Retail-Drug Stores and Proprietary StoresSEC EDGAR

CVS Health (CVS) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 31, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• Revenue and profit data not disclosed in provided text
• No segment or product line performance details available

+2 more insights

Risk Factors

• No material changes to risk factors from most recent 10-K
• Continued regulatory compliance risks including healthcare laws and data privacy regulations

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$98.9B

▲ +8.4% YoY▲ +4.6% QoQ

Net Income

$1.0B

▼ -42.3% YoY▼ -42.6% QoQ

Operating Margin

2.4%

▼ -93bp YoY▼ -116bp QoQ

Net Margin

1.0%

▼ -91bp YoY▼ -85bp QoQ

EPS (Diluted)

$0.80

▼ -42.9% YoY▼ -43.3% QoQ

Operating Cash Flow

$1.9B

▼ -38.6% YoY▼ -58.4% QoQ

Source: XBRL data from CVS Health Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other CVS Health Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on CVS Health

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.